EXPLORING AR-NFKAPPAB/P52-TARGETED INHIBITORS AS NOVEL THERAPY AGAINST CASTRATION-RESISTANT PROSTATE CANCER PROGRESSION

$112,025FY2012Department of DefenseDOD

University Of Wisconsin System, Madison WI

Investigators